• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Carcinotech

Tuesday, June 04, 2024
Company Presentation
Oncology
Company Presentation Theater 3
Carcinotech manufactures 3D-printed micro-tumors using patient-derived biopsies, primary cells, immune cells, and cancer stem cells. Our advanced offering provides a platform for rapid, ethical, and accurate drug screening, pre-clinical, and personalized medicine testing. Carcinotech’s goal is to accelerate drug screening and enable the delivery of more effective cancer treatments to market. Using patient biopsies, tissue engineering, advanced robotic manufacturing, and quality control to produce highly predictive, assay-ready printed tumors at significant throughput. This provides our clients with a “clinical biopsy” quality model, using isolated patient-specific cells and representing donor-specific cancer heterogeneity.
Carcinotech
Company Website: https://www.carcinotech.co.uk/
Lead Product in Development: Carcinotech 3D printed micro-tumours

Company HQ City

Edinburgh

Company HQ State

Midlothian

Company HQ Country

United Kingdom

CEO/Top Company Official

Ishani Malhotra (Founder & CEO)

Development Phase of Primary Product

Multiple Products in Market
Primary Speaker
Ishani Malhotra, ACA
Founder & CEO
Carcinotech
Back to Session List

white squarewhite

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS